-
公开(公告)号：US20230147040A1
公开(公告)日：2023-05-11
申请号：US17918704
申请日：2021-04-01
发明人： Motoki NAKAMURA
IPC分类号： G01N33/574 , C12Q1/26 , G01N33/50 , C12Q1/6886
CPC分类号： G01N33/5743 , C12Q1/26 , C12Q1/6886 , C12Y101/01049 , G01N33/5011 , C12Q2600/118 , C12Q2600/158 , G01N2333/904
摘要： Provided is a technique of predicting prognosis of skin cancer. A method for prognosis prediction of skin cancer includes: a step of obtaining a correlation amount correlated with an expression level of a glucose-6-phosphate dehydrogenase in a sample collected from a patient with the skin cancer; and a step of determining that the prognosis of the skin cancer is poorer when the correlation amount is large than that when the correlation amount is small.
-
公开(公告)号：US20220308073A1
公开(公告)日：2022-09-29
申请号：US17827933
申请日：2022-05-30
申请人： PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY , NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY
IPC分类号： G01N33/68
摘要： An object of the present invention is to provide a marker useful for early diagnosis and differentiation of Alzheimer's disease, and use thereof. An Alzheimer's disease biomarker composed of blood flotillin is provided.
-
公开(公告)号：US11219598B2
公开(公告)日：2022-01-11
申请号：US16094506
申请日：2017-04-19
发明人： Tsutomu Yasukawa
摘要： An object of the present invention is to provide a sustained drug release system useful for treating eye diseases. There is provided a device for sustained release of an ophthalmic drug, comprising a drug enclosing part and an intraocular retention gas enclosing part adjacent to the drug enclosing part, the enclosing parts being provided in a hollow container having at least one opening part, wherein the drug enclosing part is isolated from the opening part by the intervention of the intraocular retention gas enclosing part.
-
公开(公告)号：US11066665B2
公开(公告)日：2021-07-20
申请号：US15777498
申请日：2016-11-18
IPC分类号： C12N15/11 , C12N15/113 , A61K31/713 , A61K35/76 , A61K31/7088 , C12N15/00 , A61K9/00 , A61K47/60 , A61P35/00 , A61K9/107
摘要： This invention provides an antitumor drug delivery formulation for treating a subject having a tumor more highly expressing a TUG1 gene than normal tissues or preventing the subject from tumor metastasis, comprising a polymeric micelle comprising a nucleic acid that suppresses high expression of the TUG1 gene as an active ingredient, wherein the polymeric micelle comprises a block copolymer having a cationic poly(amino acid) segment and a hydrophilic polymer chain segment and the nucleic acid, and wherein the nucleic acid is bound to a cationic group of the cationic poly(amino acid) segment to form a complex and/or the nucleic acid is incorporated in the micelle or attached into the micelle; and the polymeric micelle accumulates in the tumor.
-
公开(公告)号：US20180291011A1
公开(公告)日：2018-10-11
申请号：US15765011
申请日：2016-10-05
发明人： Kazuki SHIMANE , Yasuhito TANAKA
IPC分类号： C07D409/04 , A61P31/20 , C07D213/80 , C07D405/10 , C07D409/10
CPC分类号： C07D409/04 , A61K31/4422 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61P31/20 , C07D213/80 , C07D405/10 , C07D409/10
摘要： An anti-hepatitis B virus agent comprising a compound represented by general formula [1], wherein R1 represents an aryl group, which may be substituted, or the like; R2 represents an aryl group, which may be substituted, or the like; and R3 represents a hydrogen atom or the like; or a salt thereof.
-
公开(公告)号：US20180163208A1
公开(公告)日：2018-06-14
申请号：US15549803
申请日：2016-02-10
发明人： Yutaka KONDO , Keisuke KATSUSHIMA
IPC分类号： C12N15/113 , A61P35/00
摘要： This invention provides a composition and a method for treating or preventing a subject having a tumor that more highly expresses a TUG1 gene than in normal tissues (e.g., brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, or lymphoma), which composition comprises, as an active ingredient, a nucleic acid that inhibits the high expression of the TUG1 gene in tumor stem cells.
-
公开(公告)号：US09700687B2
公开(公告)日：2017-07-11
申请号：US13806389
申请日：2011-06-23
申请人： Katsushi Kunimoto
发明人： Katsushi Kunimoto
IPC分类号： A61M15/00
CPC分类号： A61M15/0028 , A61M15/0026 , A61M15/0031 , A61M15/0035 , A61M15/0045 , A61M15/0048 , A61M2202/064 , A61M2205/073
摘要： It becomes possible to stably deliver an inhaled particulate medicine to a targeted part for administration while reducing burdens on a patient. When supplying the particulate medicine into a body by an airflow, a multi-layer flow composed of a core airflow (A) and a clad airflow (B) outside the core airflow is used as the airflow. The medicine is dispersed in the core airflow (A) and velocity of the clad airflow (B) is set higher than that of the core airflow (A). The medicine dispersed in the core airflow (A) reaches the targeted part for administration while the medicine is protected by the clad airflow (B) without contacting a larynx and the like. A cross-sectional area of the airflow is set smaller than that of the larynx. The airflow is supplied to an upper side of the larynx.
-
8.发明申请公开(公告)号：US20140057286A1
公开(公告)日：2014-02-27
申请号：US14051729
申请日：2013-10-11
申请人： Sysmex Corporation , National Center for Global Health and Medicine , Nagoya City University , National Institute of Advanced Industrial Science and Technology
发明人： Hisashi Narimatsu , Yuzuru Ikehara , Atsushi Kuno , Maki Sogabe , Yasuhito Tanaka , Masashi Mizokami , Kiyoaki Ito , Shunsuke Matsubara , Chikayuki Tsuruno , Youichi Takahama , Takashi Kagawa , Shinya Nagai
IPC分类号： G01N33/68
CPC分类号： G01N33/68 , C07K14/4726 , C07K14/473 , G01N33/5308 , G01N33/57438 , G01N33/6893 , G01N2333/4724 , G01N2333/4728 , G01N2400/00 , G01N2400/02 , G01N2800/085 , Y10T436/143333
摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.
摘要翻译： 本发明的目的是提供一种测定聚糖标记糖蛋白的方法，通过该方法可以以比常规方法更高的精度检测肝脏疾病。 另外，本发明的目的在于提供一种检查肝脏疾病的方法，通过该方法能够以比常规方法更高的精度检测肝脏疾病。 另外，本发明的目的在于提供一种用于上述测定方法的糖蛋白定量试剂。 此外，本发明的目的是提供聚糖标记糖蛋白作为肝病临床病症的指标，其能够根据肝病的进展来鉴定肝脏疾病的临床状况。 测定糖蛋白的方法的特征在于：糖蛋白是从受试者收集的样品中含有的至少一种糖蛋白，其选自α-1-酸糖蛋白（AGP）和Mac-2结合蛋白（M2BP） 当糖蛋白为AGP时，测量与选自AOL和MAL的第一凝集素结合的AGP; 并且当糖蛋白为M2BP时，测量与选自WFA，BPL，AAL，RCA120和TJAII的第二凝集素结合的M2BP。
-
公开(公告)号：US20110123803A1
公开(公告)日：2011-05-26
申请号：US12994087
申请日：2009-04-30
申请人： Junpei Yamanaka , Mariko Shinohara , Akiko Toyotama , Koki Yoshizawa , Sachiko Onda , Masakatsu Yonese , Fumio Uchida
发明人： Junpei Yamanaka , Mariko Shinohara , Akiko Toyotama , Koki Yoshizawa , Sachiko Onda , Masakatsu Yonese , Fumio Uchida
CPC分类号： C30B5/00 , C01B33/14 , C01B33/157 , C01B33/18 , Y10T428/298
摘要： Provided is a process for producing colloidal crystals from which a large single crystal reduced in lattice defects and unevenness can be easily produced at low cost without fail. The process for colloidal crystal production comprises: preparing a colloidal polycrystal dispersion in which colloidal crystals precipitate at a given temperature (preparation step); introducing into a vessel The colloidal polycrystal dispersion in the state of containing fine colloidal polycrystals precipitated (introduction step); and melting the colloidal polycrystals and then recrystallizing the molten polycrystals (recrystallization step). The crystals thus obtained have fewer lattice defects and less unevenness than the original polycrystals.
摘要翻译： 提供一种生产胶体晶体的方法，其中可以以低成本容易地生产晶格缺陷和不均匀性降低的大单晶。 胶体晶体生产方法包括：制备胶体晶体在给定温度下沉淀的胶态多晶分散体（制备步骤）; 引入容器沉淀含有细胶体多晶体的状态下的胶体多晶分散体（引入步骤）; 并熔化胶体多晶体，然后使熔融的多晶重结晶（重结晶步骤）。 由此获得的晶体具有比原始多晶体更少的晶格缺陷和更少的不均匀性。
-
公开(公告)号：US20230407403A1
公开(公告)日：2023-12-21
申请号：US18036733
申请日：2021-11-08
发明人： Takaya Shimura , Yusuke Okuda , Hiromi Kataoka
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/52
摘要： The present invention provides a versatile method which has a high diagnostic accuracy rate on the suitability of esophageal cancer for endoscopic therapy and enables the simple and objective determination of the suitability or unsuitability for endoscopic therapy.
In the method according to one aspect of the present invention, an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject is measured, and the expression level is compared with a reference value; the diagnostic kit according to one aspect of the present invention comprises a reagent for measuring at least one or more selected from the group consisting of the expression level of CXCL2 in the sample and the expression level of VEGFA in the sample; in the method for treating esophageal cancer according to one aspect of the present invention, the degree of vertical invasion of esophageal cancer in a subject is determined by employing a method in which an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject is measured and the expression level is compared with a reference value.
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.024 秒)
